Perspectives for prophylactic and therapeutic vaccination for HPV-induced lesions

2011 ◽  
pp. 68-79
Author(s):  
Shreya Kanodia ◽  
W Martin Kast
Keyword(s):  
Therapeutic Vaccination

scholarly journals Therapeutic vaccination for chronic hepatitis B: A systematic review and meta‐analysis

2019 ◽  
Vol 26 (7) ◽  
pp. 803-817 ◽  
Author(s):  
Seng Gee Lim ◽  
Jennielyn Agcaoili ◽  
Nurun Nisa Amatullah De Souza ◽  
Edwin Chan
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Meta Analysis ◽  
Therapeutic Vaccination

Therapeutic vaccination for chronic hepatitis B

2017 ◽  
Vol 23 ◽  
pp. 75-81 ◽  
Author(s):  
Anna D. Kosinska ◽  
Tanja Bauer ◽  
Ulrike Protzer
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Therapeutic Vaccination

Therapeutic vaccination with tumor cells that engage CD137

2003 ◽  
Vol 81 (2) ◽  
pp. 71-86 ◽  
Author(s):  
Karl Erik Hellstrom ◽  
Ingegerd Hellstrom
Keyword(s):  
Tumor Cells ◽  
Therapeutic Vaccination

scholarly journals P09.03 Hyaluronic acid as a new immunologic adjuvant in cancer: design of effective preventive and therapeutic vaccination strategies for HER2/neu-positive breast tumors

2021 ◽  
Vol 9 (Suppl 1) ◽  
pp. A28.2-A29
Author(s):  
D Carpanese ◽  
I Montagner ◽  
A Dalla Pietà ◽  
V Rossi ◽  
A Penna ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Cancer Vaccines ◽  
Tumor Regression ◽  
Vaccination Strategy ◽  
Cellular Responses ◽  
List Type ◽  
Therapeutic Vaccination ◽  
Tlr Agonist ◽  
Humoral Responses

BackgroundThe use of proteins as immunogens is attractive for the development of vaccines, but requires efficient adjuvants to overcome their weak immunogenicity. Recently, we investigated the potential of the TLR2/4 agonist hyaluronan (HA) as an immunological adjuvant for protein-based vaccines.1 2 Conjugation of HA to antigens strongly increased their immunogenicity and promoted their rapid translocation to draining lymph nodes, resulting in robust and long-lasting humoral responses.1 On these bases, we investigated the potentiality of HA-based technology in the design of cancer vaccines. To this aim, HA was conjugated to the extracellular domain of rat HER2/neu (rHER2/neu) and validated in the preventive and therapeutic vaccination settings.Materials and MethodsFemale BALB/c or BALB-neuT mice were immunized with rHER2/neu-HA. In vivo depletion of CD4+, CD8+ T and B cells was performed, and sera and spleens were collected to characterized antigen-specific humoral and cellular responses. Vaccinated BALB/c mice were challenged and re-challenged with rHER2/neu-overexpressing TUBO cells to assess the protective or therapeutic activity of rHER2/neu-HA vaccination strategy, as well as immunological memory.ResultsHA performed efficiently as robust and long-lasting humoral (IgG1, IgG2a, and IgG2b) and cellular responses were detected using very low antigen doses and number of boosters. Outstandingly, at 1-year post-vaccination, anti-rHER2/neu specific antibodies showed even improved effector functions (maturation of affinity for the receptor and increased complement-derived cytotoxicity functions). HA vaccination turned out effective in both the prophylactic (100% mice survived) and therapeutic (tumor regression in 2/12 mice) settings, and broke tolerance against rHER2/neu, delaying spontaneous tumor growth in BALB-neuT mice. Both humoral and cellular responses contributed to the success of HA-based vaccination, but CD8+ T cells played only a marginal role.ConclusionsCancer vaccines have not yet achieved significant clinical efficacy due to their poor immunogenicity, and the validation of more effective adjuvants occurred sometimes at the expense of safety. HA combines the unique immunomodulatory features of a TLR agonist with the tolerability of a fully natural polymer, proving to be a promising adjuvant for the creation of effective and safe cancer vaccines with the potential for rapid clinical translation.ReferencesDalla Pietà A, Carpanese D, et al. Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. Cell Mol Immunol 2021;18(5):1197–1210.Rosato A, Montagner IM, Carpanese D, Dalla Pietà A. Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines. 30.04.2020. WO/2020/084558, PCT/IB2019/059122.Disclosure InformationD. Carpanese: None. I. Montagner: None. A. Dalla Pietà: None. V. Rossi: None. A. Penna: None. G. Zuccolotto: None. G. Pasut: None. A. Grigoletto: None. A. Rosato: None.

Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41

2008 ◽  
Vol 134 (5) ◽  
pp. 1385-1395.e1 ◽  
Author(s):  
Christoph S. Klade ◽  
Heiner Wedemeyer ◽  
Thomas Berg ◽  
Holger Hinrichsen ◽  
Grazyna Cholewinska ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Peptide Vaccine ◽  
Therapeutic Vaccination

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

Vaccine ◽  
2002 ◽  
Vol 20 (17-18) ◽  
pp. 2343-2347 ◽  
Author(s):  
Catharina E.A. Lindenburg ◽  
Ineke Stolte ◽  
Miranda W. Langendam ◽  
Frank Miedema ◽  
Ian G. Williams ◽  
...  
Keyword(s):  
Disease Progression ◽  
Therapeutic Vaccination ◽  
Virus Like Particles ◽  
Long Term Follow Up ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document